A Launchpad For Scalable And Optimized Systems In AAV Gene Therapy Manufacturing

The number of viral vector treatments approved by regulators in the last decade, combined with the increasing number of these therapies in various phases of development, has positioned these modalities as the primary delivery mechanism for cell and gene therapies for the foreseeable future. The resulting demand for viral vectors continues to increase, making addressing the challenges related to their manufacturing and scale-up increasingly critical. As the vehicle that delivers a payload to target cells, viral vectors are subject to a slew of considerations impacting their yields, scalability, and overall optimization.

From choosing a vector – and a serotype – to achieving the quality, productivity, and consistency necessary to shepherd an asset through development, the variables that impact viral vector modalities have necessitated greater focus and more novel approaches within the advanced therapy space. For many companies, accessing the expertise needed to optimize around factors such as media feeds, cell densities, vector design, plasmid optimization, process control, and upstream process improvements can unlock new potential for their asset and greatly streamline development.